Overview

University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the safety and efficacy of a single, intravenous dose of suramin in autism spectrum disorders (ASD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Diego
Treatments:
Suramin